Clinical Rheumatology

, 29:209 | Cite as

Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet’s disease

Case Report


Familial Mediterranean fever (FMF) is associated with mutations in the gene coding for pyrin which lead to accentuated innate immune responses resulting in increased production of IL-1. We present a teenager who had severe FMF and Behçet’s disease and developed moderate proteinuria. Renal biopsy showed secondary amyloidosis. Anakinra was started at 1 mg/kg/day subcutaneously along with colchicine treatment. The clinical response was excellent. Acute phase reactants decreased. The level of proteinuria and renal functions remained stable and the hypoalbuminemia returned to normal. Her clinical and laboratory symptoms returned when anakinra had to be stopped at 6 months. Thus, the drug was restarted and she is now clinically in excellent condition a year after the start of therapy. She has normal renal functions, normal serum proteins, and normal acute-phase reactants. However, recently, after 18 months of anakinra treatment, her proteinuria gradually increased and albumin levels decreased. We suggest that anti-IL-1 treatment is beneficial for the suppression of inflammation; however, long-term studies are needed to understand whether progressive renal disease will be prevented.


Anakinra Amyloidosis Behçet disease FMF 


  1. 1.
    Staganov S, Kastner DL (2005) Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 17(5):586–599CrossRefGoogle Scholar
  2. 2.
    Ozen S (2003) Familial Mediterranean fever: revisiting an ancient disease. Eur J Pediatr 162(7–8):449–454CrossRefPubMedGoogle Scholar
  3. 3.
    Samuels J, Ozen S (2006) Familial Mediterranean fever and the other autoinflammatory syndromes: evaluation of the patient with recurrent fever. Curr Opin Rheumatol 18(1):108–117CrossRefPubMedGoogle Scholar
  4. 4.
    Gül A (2005) Behçet’s disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy 4:81–83CrossRefPubMedGoogle Scholar
  5. 5.
    Yurdakul S, Tuzuner N, Yurdakul I, Hamuryudan V, Yazıcı H (1990) Amyloidosis in Behçet’s syndrome. Arthritis Rheum 33:1586–1589CrossRefPubMedGoogle Scholar
  6. 6.
    Galon J, Aksentijevich I, McDermott MF, O’Shea JJ, Kastner DL (2000) TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol 12(4):479–486CrossRefPubMedGoogle Scholar
  7. 7.
    Chae JJ, Wood G, Masters SL, Richard K, Park G, Smith BJ, Kastner DL (2006) The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1 β production. Proc Natl Acad Sci USA 103(26):9982–9987CrossRefPubMedGoogle Scholar
  8. 8.
    Calligaris L, Marchetti F, Tommasini A, Ventura A (2008) The efficacy of anakinra in an adolescent with colchicine resistant familial Mediterranean fever. Eur J Pediatr 167(6):695–696CrossRefPubMedGoogle Scholar
  9. 9.
    Hawkins PN, Lachmann HJ, McDermott MF (2003) Interleukin 1 receptor antagonist in the Muckle–Wells syndrome. N Engl J Med 348(25):2583–2584CrossRefPubMedGoogle Scholar

Copyright information

© Clinical Rheumatology 2009

Authors and Affiliations

  1. 1.Department of Pediatrics, Nephrology and Rheumatology UnitHacettepe University School of MedicineAnkaraTurkey

Personalised recommendations